ValuEngine Upgrades Agenus (NASDAQ:AGEN) to “Hold”

ValuEngine upgraded shares of Agenus (NASDAQ:AGEN) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning, ValuEngine reports.

Separately, BidaskClub raised shares of Agenus from a strong sell rating to a sell rating in a research report on Tuesday, November 5th.

Shares of AGEN stock traded down $0.11 on Wednesday, reaching $3.57. The company had a trading volume of 1,969,700 shares, compared to its average volume of 1,169,610. The business’s 50-day moving average is $2.72 and its 200 day moving average is $2.74. Agenus has a one year low of $1.86 and a one year high of $3.88. The stock has a market capitalization of $443.52 million, a PE ratio of -2.48 and a beta of 1.84.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.05. The business had revenue of $19.94 million during the quarter, compared to analyst estimates of $15.60 million. On average, sell-side analysts forecast that Agenus will post -0.96 earnings per share for the current year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Commonwealth Equity Services LLC acquired a new stake in Agenus in the 3rd quarter valued at $27,000. Bank of Montreal Can lifted its stake in Agenus by 443.8% during the 2nd quarter. Bank of Montreal Can now owns 10,675 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 8,712 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Agenus during the 2nd quarter valued at $34,000. Cambridge Investment Research Advisors Inc. bought a new position in Agenus during the 2nd quarter valued at $40,000. Finally, Jefferies Group LLC bought a new position in Agenus during the 2nd quarter valued at $44,000. 35.23% of the stock is owned by institutional investors and hedge funds.

About Agenus

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Recommended Story: What are no-load funds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Leave a Reply

Your email address will not be published. Required fields are marked *